Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials

Dec 02 2013

• By Emily Hayes

Related Content

New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal

Sep 01 2008

No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT

Apr 07 2008

More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit

May 26 2011

Time, And Price, Are Right To Prescribe Statins To the Masses

Dec 02 2013

<em>Tredaptive</em> Safety Hazards Cast Shadow Over AbbVie’s <em>Niaspan</em>

Mar 18 2013

HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers

Mar 18 2013

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

May 14 2012

Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster

May 07 2012

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Dec 11 2006

Big Pharma’s Gamble On HDL Hypothesis

Apr 23 2012

AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug

Dec 23 2010

Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Mar 14 2010

Panel To Weigh Amarin’s Expanded <em>Vascepa</em> Use Given Clinical Outcome Concerns

Oct 11 2013

Related Companies

Pfizer Inc.

Merck & Co., Inc.

AbbVie Inc.

BASF AG

GSK plc

Additional Topics

Clinical Trials

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window